Results 81 to 90 of about 543 (171)

Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany. [PDF]

J Cancer Res Clin Oncol
Janke FF, Baldessarini RJ, Bauerschlag D, Zibolka S, Hartmann M.   +4 more
europepmc   +1 more source

Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians. [PDF]

Prev Med Rep, 2022
Mocek A, Weber V, Schmölders J, Witt H, Gothe H.   +4 more
europepmc   +1 more source

Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]

Appl Health Econ Health Policy
Gandjour A.
europepmc   +1 more source

Authors' Reply to Gandjour: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]

Appl Health Econ Health Policy
Büssgen M, Stargardt T.
europepmc   +1 more source

Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China. [PDF]

Regen Ther
Shi J, Hu H, Ung COL.
europepmc   +1 more source

Availability of New Medicines in the US and Germany From 2004 to 2018.

JAMA Netw Open, 2022
Blankart K, Naci H, Chandra A.
europepmc   +1 more source

Primary endpoint acceptance and its association with benefit ratings and market access in German health technology assessments: a retrospective cohort study. [PDF]

Lancet Reg Health Eur
Müller G, Granold M, Busse R, Hahn A.
europepmc   +1 more source

I tetti sulla spesa per i farmaci nel quadro delle azioni di governo dell’assistenza farmaceutica: criticità e opzioni per una riforma. [PDF]

Glob Reg Health Technol Assess
Jommi C.
europepmc   +1 more source

[Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps]. [PDF]

HNO, 2021
Klimek L, Chaker A, Deitmer T, Plontke SK, Wollenberg B, Bousquet J, Bachert C.   +6 more
europepmc   +1 more source